Vernalis plc

Vernalislog

 

Vernalis plc, the parent company of Vernalis Therapeutics, Inc. is one of the UK’s leading pharmaceutical companies, Vernalis takes promising product candidates along a commercially-focused path to market. We derive pipeline candidates both from successful collaborations with a number of global pharmaceutical businesses, our own research activities and from in-licensing. 

 The strategy is to:

  • Build a profitable and cash generative business
  • Develop and commercialise low development-risk late-stage differentiated pharmaceutical products for unmet medical needs in the US
  • Partner all of our NCE drug candidates
  • Leverage our structure- and fragment-based drug discovery expertise through collaborations with other companies

For more information please visit us at www.vernalis.com.

 

Latest News

Results Announcement for the year ended 30 June 2017

Vernalis plc (LSE: VER) today announces its audited financial results for the year ended 30 June 2017, following the year-end trading update published on 18 July 2017.

Read more ...

Fact Sheet

For more information on Vernalis, click below to download a copy of our fact sheet

 

Factsheet-Nov14

 

 

 

 

Contact Vernalis Therapeutics

T: 1-484-913-0700
F: 1-610-651 5976

Contact information
Maps and directions
Contact form

To report SUSPECTED ADVERSE REACTIONS, contact Vernalis Therapeutics, Inc. at 1-855-705-9546 and drugsafety@propharmagroup.com or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch